ZEB1 and muscle atrophy: Downregulation of ZEB1 in some of these non-epithelial cells is linked to the development or exacerbation of various physiopathological conditions and diseases (e.g., corneal dystrophy, muscle atrophy, muscular dystrophy, osteoporosis, post-ischemic brain damage and, shown here, atherosclerosis plaque formation) and transient or stably ZEB1 overexpression has been used to treat these conditions in preclinical models30,36,82–84.